Core Viewpoint - Zeling Bio has submitted its IPO application to the Hong Kong Stock Exchange, marking its official attempt to go public [1] Group 1: Company Overview - Zeling Bio, founded in 2019, is an innovative biotechnology company focused on late-stage clinical development [4] - The company was incubated under the incentive policies for technology transfer from Sichuan University West China Hospital [2] - The founder, Dr. Chen Lijuan, has extensive experience in the biotechnology industry and holds multiple degrees in chemistry and pharmacy [4][6] Group 2: Financial Information - Zeling Bio recently completed a C-round financing of nearly 600 million RMB, led by Daming Capital and Qiming Venture Partners, bringing its valuation to approximately 3.411 billion RMB [2][8] - The company has raised a total of about 1.18 billion RMB across five financing rounds since its inception [8] - Financial data shows that Zeling Bio reported a net loss of 91.656 million RMB for the fiscal year 2024, with losses expanding to 119.043 million RMB in the first three quarters of 2025 [12][13] Group 3: Product Pipeline - The company has a pipeline of eight products, including two core products in Phase III clinical trials and two candidates in clinical stages [11] - The lead product, Fluorotinib, is aimed at treating myeloproliferative neoplasms, with plans to submit a new drug application to the National Medical Products Administration in 2027 [11][10] - Zeling Bio has not yet commercialized any products and has not generated revenue from product sales [12]

Core Viewpoint - The China Securities Regulatory Commission (CSRC) has requested additional compliance information from Chengyi Biotechnology regarding its overseas listing application, focusing on three main areas: equity structure, capital situation, and domestic operating entities [1][2][3] Group 1: Compliance Requirements - The CSRC requires Chengyi Biotechnology to clarify the compliance of its equity structure and reverse mergers, including whether shareholders holding over 5% have completed foreign exchange registration and if domestic institutional shareholders have followed necessary regulatory procedures [2] - The company must explain the pricing basis and tax payments related to acquisitions of domestic entities, ensuring compliance with regulations on foreign investment in domestic enterprises [2] - The CSRC also demands a conclusion on whether the equity structure and reverse merger processes adhered to existing foreign exchange management, foreign investment, and tax regulations [2] Group 2: Capital Situation - The CSRC has asked for clarification on the shareholding proportions of key stakeholders and whether they should be consolidated, as well as the specific arrangements regarding special shareholder rights and their impact on control [3] - The company is required to disclose whether there have been any shareholding proxies in its historical evolution and if the pricing for new shareholders in the last 12 months was fair and reasonable [3] - The CSRC seeks a conclusive opinion on whether the equity incentives involving domestic individuals complied with foreign exchange registration requirements [3] Group 3: Domestic Operating Entities - Chengyi Biotechnology must provide details on its wholly-owned subsidiary, Shanghai Chengyi, which holds a patent for an extracellular gene expression intervention method, and whether its business aligns with the negative list of foreign investment access [3] - The company is required to disclose any significant litigation, arbitration, or administrative penalties affecting its domestic operations [3] - A conclusive opinion on the legality and compliance of the establishment and historical equity changes of domestic operating entities is also required [3] Group 4: Financial Performance - Chengyi Biotechnology reported revenues of $36.06 million, $221 million, and $557,000 for the years 2023, 2024, and the first half of 2025, respectively, with net profits of -$52.23 million, $139 million, and -$20.11 million during the same periods [4] - The company has only one customer, AstraZeneca, which is also a shareholder, generating revenues of $36 million, $221 million, and $55,680 from this customer in the respective years [4] Group 5: Competitive Landscape - Chengyi Biotechnology believes its pipeline strength and proprietary TRANDD platform provide a significant competitive advantage, but it faces potential competition from multinational pharmaceutical companies and other biotech firms [5] - The company heavily relies on the success of its candidate drugs, and any failure to complete development, obtain regulatory approval, or commercialize these drugs could significantly harm its business and financial outlook [5]

Group 1: Company Overview - Chengdu Zeling Biopharmaceutical Technology Co., Ltd. (Zeling Bio) has submitted its prospectus for an IPO on the Hong Kong Stock Exchange, with Jefferies and CICC as joint sponsors [1] - The company recently completed a C round financing of nearly 600 million RMB, led by Daming Capital and Qiming Venture Partners, bringing its valuation to approximately 3.411 billion RMB [1] - Zeling Bio was founded in 2019 and focuses on innovative therapies for blood diseases, tumors, central nervous system disorders, and immune/inflammatory diseases [2] Group 2: Product Pipeline - Zeling Bio has established three technology platforms: ZeniFol for small molecule drug identification and optimization, ZeniMin for AI-driven drug development, and ZeniScreen for clinical-related screening and target discovery [2] - The company has a pipeline of eight products, including two core products in Phase III clinical trials, two candidates in clinical stages, and four in preclinical stages [3] Group 3: Key Products - The lead product, Malate Fluorotinib (FM), is a first-in-class triple-target inhibitor aimed at treating myeloproliferative neoplasms, including myelofibrosis and polycythemia vera [4] - FM is positioned against Novartis' Ruxolitinib, which has been a cornerstone therapy since its approval in the U.S. in 2011 [4] - Zeling Bio plans to submit a new drug application for FM to the National Medical Products Administration (NMPA) in 2027 and has initiated a Phase IIb head-to-head clinical trial against Ruxolitinib [6] Group 4: Financial Performance - Zeling Bio reported revenues of 19.66 million RMB and 7.12 million RMB for 2024 and the first three quarters of 2025, respectively, with significant losses of 91.66 million RMB and 119.04 million RMB during the same periods [9] - The primary reasons for the losses are high R&D expenditures and changes in the value of redeemable debt, with a significant focus on the two core products FM and PM [10] Group 5: Funding and Shareholding - The company has completed five rounds of financing, raising a total of 1.18 billion RMB, with investors including Qiming Venture Partners and Tencent [12] - Chen Lijuan holds a combined direct and indirect stake of 25.6%, making her the largest shareholder group [14]

Core Viewpoint - 英矽智能 has entered into an exclusive licensing and co-development agreement with Shenzhen Hengtai Biotechnology Co., Ltd. for the ISM8969 project, aimed at accelerating the global development of a new oral NLRP3 inhibitor for central nervous system diseases [1] Group 1: Agreement Details - The agreement grants Shenzhen Hengtai the rights to research, develop, register, produce, and commercialize ISM8969 globally, with both parties holding 50% global rights to the project [1] - 英矽智能 is entitled to receive up to $66 million (approximately HKD 514.8 million) in upfront and milestone payments, including an expected upfront payment of $10 million (approximately HKD 78 million) within 30 days of the agreement's effective date [1] Group 2: Company Background - Shenzhen Hengtai Biotechnology Co., Ltd. was incubated by Shenzhen Pengfu Biomedical Industry Private Equity Investment Fund Partnership and Fosun Pharma, focusing on innovative biotechnology in the field of autoimmune diseases [1] - Established in August 2025, the company aims to introduce and develop innovative pipelines with "best-in-class" potential globally, providing breakthrough treatment solutions through efficient R&D and commercialization capabilities [1]

Core Viewpoint - The announcement details the upcoming listing and circulation of restricted shares for Beijing Innotech Biotechnology Co., Ltd., with a total of 67,647,516 shares set to be released on January 28, 2026, representing 49.3834% of the company's total share capital [1][13]. Group 1: Listing Details - The type of shares being listed is the first issuance of restricted shares, with a total of 67,647,516 shares available for circulation [1]. - The shares were initially issued on July 28, 2022, with a total share capital of 136,060,816 shares, of which 107,471,765 shares are restricted [1][3]. - The restricted shares will be released after a lock-up period of 42 months, extended from the original 36 months due to shareholder commitments [3]. Group 2: Shareholder Commitments - Major shareholders, including the actual controllers, have committed to not transferring their shares for 36 months post-listing, with additional conditions for any subsequent sales [5][10]. - The commitments include a stipulation that any share sales within two years after the lock-up period must not be below the initial offering price [10][11]. - The company has confirmed that all shareholders have adhered to their commitments, ensuring compliance with relevant regulations [12][13]. Group 3: Capital Structure Changes - The company's total share capital has changed from 136,060,816 shares to 136,458,196 shares due to the completion of the first vesting period of the 2023 restricted stock incentive plan [4]. - Further changes in share capital are expected as additional vesting periods are completed in the future [4]. Group 4: Regulatory Compliance - The underwriting institution, Huatai United Securities Co., Ltd., has verified that the listing of restricted shares complies with relevant laws and regulations [12][13]. - The announcement confirms that the information disclosed regarding the restricted shares is accurate and complete [13].

Group 1: IPO Activity Overview - Last week, one small IPO and three SPACs completed pricing, with a total of eight IPO companies (including five larger firms) and one SPAC filing for listings [1][2] - Green Circle Decarb Tech (GCDT), a Chinese producer of thermal energy storage materials, raised $10 million at a market cap of $50 million, with its stock price increasing by 14% [1][2] - Infinite Eagle Acquisition (IEAGU) raised $300 million, OneIM Acquisition (OIMAU) raised $250 million, and FG Imperii Acquisition (FGIIU) raised $200 million, all targeting various sectors [1][2] Group 2: Upcoming IPOs - Eight companies filed for IPOs last week, with five planning to raise over $100 million, led by Brazilian digital bank AGI (AGBK) aiming for approximately $1 billion [2][4] - Liftoff Mobile (LFTO) plans to raise about $800 million, while SOLV Energy (MWH) aims for around $750 million [2][4] Group 3: Future IPOs and Market Outlook - EquipmentShare.com (EQPT) plans to raise $747 million, with a post-IPO market cap exceeding $6.7 billion, focusing on equipment rental services [5] - BitGo Holdings (BTGO) aims for a $2 billion valuation while raising $189 million, providing a digital asset custody and trading platform [6][7]

一、关于股权架构搭建及返程并购的合规性，请说明（1）持股5%以上的股东是否履行《关于境内居民 通过特殊目的公司境外投融资及返程投资外汇管理有关问题的通知》（37号文）的外汇登记，以及境内 机构股东是否履行对外投资等境内监管程序；（2）红筹架构搭建过程中，涉及收购境内主体的，请说 明交易对价、定价依据、税费缴纳等情况，是否符合《关于外国投资者并购境内企业的规定》；（3） 境内运营主体历史上涉及减资的，请说明交易对价、定价依据及公允性，相关决策程序履行及税费缴纳 情况，是否存在虚假出资、抽逃出资，是否符合《公司法》和税收相关法律法规；（4）股权架构搭建 及返程并购过程符合当时有效的外汇管理、境外投资、外商投资、税务管理等监管规定的结论性意见。 二、关于股本情况，请说明（1）杭州阿斯利康中金与AstraZeneca UK Limited的持股比例是否应合并计 算，应否按照5%以上股东标准对杭州阿斯利康中金进行核查说明；（2）特殊股东权利中董事及观察员 选任权的具体安排以及是否影响控制权认定，上市前后控制权存在变化的应充分说明；（3）公司的历 史沿革中是否存在股份代持；（4）最近12个月内新增股东入股价格是否公允、合 ...

Core Viewpoint - The announcement highlights a collaboration between HBM Alpha Therapeutics and Spruce Biosciences to develop novel CRH-targeted therapies for various diseases, indicating a strategic move in the biopharmaceutical sector [1] Group 1: Partnership Details - HBM Alpha Therapeutics has entered into a licensing and collaboration agreement with Spruce Biosciences Inc. to advance new CRH-targeted therapies [1] - Under the agreement, HBMAT and its affiliates will receive warrants related to minority equity to purchase common stock of Spruce [1] Group 2: Equity Stake - As of January 19, 2026, the company and HBMAT will exercise the warrants, resulting in the company holding approximately 3.8% of Spruce's outstanding shares and about 3.1% of Spruce's fully diluted shares [1]

Core Viewpoint - HBM Alpha Therapeutics (HBMAT), a biotech company incubated by the company, has entered into a licensing and collaboration agreement with Spruce Biosciences Inc. to advance novel corticotropin-releasing hormone (CRH) targeted therapies for various diseases [1] Group 1 - The agreement allows HBMAT and its affiliates to acquire warrants related to a minority equity stake to purchase common shares of Spruce [1] - The company and HBMAT plan to exercise the warrants on January 19, 2026, which will result in the company holding approximately 3.8% of Spruce's outstanding shares and about 3.1% of Spruce's fully diluted shares [1]

Core Viewpoint - HBM Alpha Therapeutics, a biotech company incubated by the company, has entered into a licensing and collaboration agreement with Spruce Biosciences to advance novel CRH-targeted therapies for various diseases [1] Group 1: Agreement Details - The agreement allows HBMAT and its affiliates to obtain warrants related to minority equity to purchase common stock of Spruce [1] - The company and HBMAT will exercise the warrants on January 19, 2026 [1] Group 2: Equity Holdings - Upon exercising the warrants, the company will hold approximately 3.8% of Spruce's outstanding shares and about 3.1% of Spruce's fully diluted shares [1]